BostonGene Wins Frost & Sullivan Award for AI in Precision Oncology

BostonGene has been awarded the 2025 North American Enabling Technology Leadership Award by Frost & Sullivan for its pioneering role in precision oncology, announced in a press release. The company's AI-powered platform integrates multiomics data, including genes, RNA, proteins, and the tumor environment, to accelerate drug development and improve clinical outcomes.

BostonGene's platform, known for its "Comprehensive Digital Patient" model, aids pharmaceutical and biotech companies in developing targeted therapies and designing efficient clinical trials. The platform's ability to decode diseases and uncover predictive biological signatures has been recognized for its impact on both research and real-world clinical settings.

The award highlights BostonGene's state-of-the-art analytics technologies, which are supported by a CLIA-certified and CAP-accredited laboratory infrastructure. This recognition underscores the company's commitment to providing drug developers with tools for smarter, faster decision-making in oncology drug development.